PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 190 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 5.26 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $28,488,294 | +54.6% | 822,173 | +29.1% | 0.27% | +60.0% |
| Q1 2024 | $18,427,137 | +56.1% | 636,956 | +49.1% | 0.17% | +21.4% |
| Q2 2023 | $11,801,032 | -17.1% | 427,264 | -30.9% | 0.14% | -27.8% |
| Q1 2023 | $14,228,145 | +154.6% | 618,615 | +20.8% | 0.19% | +158.7% |
| Q4 2022 | $5,587,447 | +81.8% | 512,140 | +31.8% | 0.08% | +59.6% |
| Q2 2022 | $3,074,000 | -77.9% | 388,637 | -34.0% | 0.05% | -79.2% |
| Q1 2022 | $13,940,000 | -17.3% | 588,694 | +19.4% | 0.23% | -6.6% |
| Q4 2021 | $16,860,000 | – | 492,987 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |